Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130)

BACKGROUND: In the randomised Phase 3 IMpassion130 trial, atezolizumab combined with nab-paclitaxel (atezo + nab-P) in 902 patients with triple-negative breast cancer (TNBC) showed prolonged progression-free survival (PFS) in both the intention-to-treat (ITT) population and programmed death-ligand 1...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Jpn J Clin Oncol
Hlavní autoři: Iwata, Hiroji, Inoue, Kenichi, Kaneko, Koji, Ito, Yoshinori, Tsugawa, Koichiro, Hasegawa, Ayumi, Nakagawa, Shintaro, Kuratomi, Hiroyasu, Tamura, Kenji
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2019
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6935297/
https://ncbi.nlm.nih.gov/pubmed/31612909
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jjco/hyz135
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky